Matching articles for "November 19"
Issue 1274 · November 19, 2007 Free
BRCA Screening

Direct-to-consumer advertisements are urging women to be tested for mutations in BRCA1 and BRCA2 genes, which are the most common known causes of an inherited predisposition to breast and ovarian cancer.…

Med Lett Drugs Ther. 2007 Nov 19; 49(1274):93-4
Direct-to-consumer advertisements are urging women to be tested for mutations in BRCA1 and BRCA2 genes, which are the most common known causes of an inherited predisposition to breast and ovarian cancer. Clinically important BRCA mutations have been found in about 2% of Ashkenazi Jewish women, and are estimated to occur in about 1 in 300 to 500 women in the general non-Jewish US population. The prevalence appears to be lower in non-whites.
Issue 1274 · November 19, 2007
Formoterol (Perforomist) for COPD

Formoterol fumarate ( Perforomist - Dey), a long-acting beta 2 -agonist, was recently approved by the FDA as an inhalation solution for nebulization for maintenance treatment of bronchoconstriction associated…

Med Lett Drugs Ther. 2007 Nov 19; 49(1274):94-5
Formoterol fumarate ( Perforomist - Dey), a long-acting beta 2 -agonist, was recently approved by the FDA as an inhalation solution for nebulization for maintenance treatment of bronchoconstriction associated with chronic obstructive pulmonary disease (COPD). Arformoterol (Brovana) , the (R, R)-enantiomer of formoterol, was approved earlier this year for the same indication.
Issue 1274 · November 19, 2007
SSRIs and Osteoporosis

Some recently published studies suggest that taking selective serotonin reuptake inhibitors (SSRIs) may increase the risk of developing osteoporosis. A relationship between SSRIs and osteoporosis is…

Med Lett Drugs Ther. 2007 Nov 19; 49(1274):95-6
Some recently published studies suggest that taking selective serotonin reuptake inhibitors (SSRIs) may increase the risk of developing osteoporosis. A relationship between SSRIs and osteoporosis is biologically plausible because bone has serotonin receptors, and SSRI-treated mice have reduced bone mass.
Issue 1274 · November 19, 2007 Free
In Brief: Varenicline (Chantix) Revisited

When the nicotine receptor partial agonist varenicline ( Chantix – Pfizer) was first marketed, The Medical Letter concluded that it was moderately effective in increasing smoking cessation rates. 1 More…

Med Lett Drugs Ther. 2007 Nov 19; 49(1274):93-6
When the nicotine receptor partial agonist varenicline ( Chantix – Pfizer) was first marketed, The Medical Letter concluded that it was moderately effective in increasing smoking cessation rates. 1 More recent publications and the clinical experience of Medical Letter consultants now suggest that varenicline is the most effective drug available for this indication, more effective than nicotine replacement therapy or bupropion SR (Zyban) . 2,3 A word of caution: exacerbations of psychiatric illness have been reported in patients who took higher-than-recommended starting doses of varenicline. 4,5 1. Varenicline (Chantix) for tobacco dependence. Med Lett Drugs Ther 2006; 48:66. 2. P Wu et al. Effectiveness of smoking cessation therapies: a systemic review and meta-analysis. BMC Public Health 2006; 6:300. 3. K Cahill et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007; (1):CD006103. 4. R Freedman. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007; 164:1269. 5. I Kohen and N Kremen. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007; 164:1269. Download U.S. English